Breaks Categories: News

TuesdayJan 03, 2023 2:05 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Letter to Shareholders

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has published a letter from CEO Amir Reichman. The letter provides an overview of 2022 accomplishments, including the company’s successful preclinical trial results of the inhaled COVID-19 NanoAb therapy, along with a report of recent financing activities to support 2023 objectives. Highlights of the letter include the signing a series of collaboration agreements with the Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen, Germany (“UMG”) for the development of NanoAbs…

Continue Reading

ThursdayDec 29, 2022 11:40 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Shareholder Letter, Including Corporate Update

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has issued a letter to shareholders. The letter, signed by HeartBeam CEO and founder Branislav Vajdic noted that 2022 was a “transformative” year for HeartBeam, highlighted by ongoing advancements in the company’s product launch timeline for the HeartBeam AIMIGo(TM) 12-Lead 3D Vector Electrocardiogram (“ECG”) device and HeartBeam AIMI(TM). Vajdic stated that he could not be more enthusiastic about the future of the company or its ability to scale the commercialization path. He also pointed out that…

Continue Reading

ThursdayDec 22, 2022 11:07 am

BioMedNewsBreaks – Aegis Capital Corp. Acted as Sole Bookrunner on BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) $8M Underwritten Public Offering

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Aegis Capital Corp., which is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions, acted as sole bookrunner on an $8 million underwritten public offering for BiondVax Pharmaceuticals. BiondVax expects to use the net proceeds from the offering, together with its existing cash and cash equivalents, for the advancement of its nanosized antibody (“NanoAb”) development program and general corporate purposes. To view the full…

Continue Reading

TuesdayDec 20, 2022 2:22 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Closes $8M Underwritten Public Offering

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the closing of its underwritten public offering with gross proceeds to the company to be $8,000,000. The offering consists of 1,600,000 units and pre-funded units, with each unit consisting of one American Depositary Share (“ADS”) and two warrants, each to purchase one ADS. Each pre-funded unit consists of one pre-funded warrant to purchase one ADS and two warrants each to purchase one ADS. BiondVax expects to use the net proceeds, together with its existing…

Continue Reading

TuesdayDec 20, 2022 11:59 am

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Files Updated Life Sciences Presentation

India Globalization Capital (NYSE American: IGC) today announced the filing of a life sciences presentation with the SEC on Form 8K. The presentation, available on the SEC website as well as published to IGC’s website, provides an overview of the company’s initiatives in life sciences. These include IGC’s focus on low-dose THC-based drug formulation and disease treatment and its various lines of cannabinoid-based consumer products. To view the full press release, visit https://ibn.fm/SmE91 About India Globalization Capital Inc. India Globalization Capital, through its subsidiary IGC Pharma LLC, develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s,…

Continue Reading

TuesdayDec 20, 2022 11:13 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO Highlights 2022 as ‘Momentous Year’

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today issued a year-end summary of its key milestone accomplishments in 2022. “2022 was a momentous year marked by steady progress across our pipeline of differentiated psychedelic-based therapeutics and partnerships targeting mental health. Most notable were the advancements of our two lead programs, CYB003 and CYB004, into clinical stage – within less than 18 months since discovery – which is a remarkable accomplishment and a true testament to the strength of our team,” said Cybin’s Chief Executive Officer Doug Drysdale. “Along with our clinical programs,…

Continue Reading

FridayDec 16, 2022 12:12 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Pricing on Public Offering, Expects to Raise $8M

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the pricing of its underwritten public offering. According to the announcement, the company anticipates gross proceeds from the offering, which consists of 1,600,000 units and prefunded units, to reach an estimated $8 million. The company specified that each unit consists of one American Depositary Share (“ADS”) and two warrants; one warrant will expire three years from the date of issuance with the second warrant set to expire one year from the date of issuance.…

Continue Reading

FridayDec 16, 2022 10:22 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Shares Annual General Meeting Results

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, is reporting on the results of its 2022 annual meeting. The meeting of shareholders was held Dec. 15, 2022. During the meeting, shareholders considered and voted on all matters outlined in InMed’s notice of meeting and management information circular. Specifically, the election of directors was held, and shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders. Those directors included Eric Adams, Andrew Hull, Janet Grove, Bryan Baldasare, and Nicole Lemerond. To view…

Continue Reading

WednesdayDec 14, 2022 3:55 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Approval to Dual List, to Commence Trading on Upstream

Nutriband (NASDAQ: NTRB, NTRBW) has announced its approval to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited. The company’s trading is expected to commence on Upstream under ticker symbol NTRB at 10:00am ET on Jan. 5, 2023. “Building shareholder value and increasing our liquidity is always a high priority for us,” said Gareth Sheridan, CEO of Nutriband. “We believe a dual listing on Upstream will act as an excellent vehicle to reach an untapped international market of potential new shareholders. As we continue to develop…

Continue Reading

WednesdayDec 14, 2022 2:14 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Berubicin Program Forward

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments, recently announced that the first patient in Europe had been enrolled and dosed in France in the company’s ongoing global trial to evaluate Berubicin for the treatment of recurrent glioblastoma multiforme (“GMB”), an aggressive and incurable form of brain cancer. “Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier (based upon pre-clinical and limited clinical data) and is currently being evaluated in the potentially pivotal study evaluating efficacy and safety for GBM treatment. This study is an adaptive,…

Continue Reading